What is the role of nintedanib in the treatment of SSc-ILD?
The SENSCIS trial was published in 2019 on efficacy of this agent. However, it's not clear where this should be in the treatment algorithm: Monotherapy vs combination? First line or second line?
2 Answers
Mednet MemberInvited Expert
Rheumatology · The University of Texas Health Science Center at Houston (UTHealth Houston)
Answered on
Nintedanib has shown to be effective for treating patients with ILD associated with systemic sclerosis, as the annual rate of decline in FVC was lower with nintedanib than with placebo (SENSCIS trial). However, the majority of patients treated with nintedanib in this trial were also on MMF therapy. ...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Rheumatology · Louisiana State University and Tulane University Schools of Medicine
Answered on · Updated on
Dr. McMahan's answer supports the striking difference in the primary endpoint selection in the trial designs and results between nintedanib (Distler et al., PMID 31112379) and both Scleroderma Lung Study (SLS) I and II.
Equally striking were the statistically significant results in the secondary endp...
Join for free or sign in to see the full answer